These results were validated in a retrospective cohort of EGFR-mutant NSCLC patients who received a single line of EGFR TKI including osimertinib, with 20% of post-treatment samples having PPP3CB mRNA accumulation without any known genetic mechanism of acquired resistance. The gene discussed is PPP3CB; the disease is non-small cell lung carcinoma.